Vascular‐targeted nanocarriers are an attractive option for the treatment of a number of
cardiovascular diseases, as they allow for more specific delivery and increased efficacy of …

Nanomedicine approaches have revolutionized the treatment of cancer and vascular
diseases, where the limitations of rapid nonspecific clearance, poor biodistribution and …

This issue of the journal is dedicated to targeted delivery of therapeutics in the vasculature,
an approach that holds promise to optimize treatment of diverse pathological conditions …

Atherosclerosis (AS) has emerged as one of the prevalent arterial vascular diseases
characterized by plaque and inflammation, primarily causing disability and mortality globally …

Atherosclerosis, a highly prevalent cardiovascular disease, has significantly contributed to
morbidity and mortality worldwide. Despite the availability of various treatment options in …

Targeted nanomedicine holds promise to find clinical use in many medical areas.
Endothelial cells that line the luminal surface of blood vessels represent a key target for …

Cardiovascular diseases (CVDs) are the leading cause of death and morbidity worldwide.
Atherosclerotic situations such as acute myocardial infarction (MI) and stroke are still major …

Atherosclerosis (AS) is a leading cause of the life-threatening cardiovascular disease (CVD),
creating an urgent need for efficient, biocompatible therapeutics for diagnosis and treatment …

Atherosclerosis is a chronic and metabolic-related disease that is a serious threat to human
health. Currently available diagnostic and therapeutic measures for atherosclerosis lack …

Nanocarriers (NCs) coated with antibodies (Abs) to extracellular epitopes of the
transmembrane glycoprotein PECAM (platelet endothelial cell adhesion molecule-1/CD31) …